ArticleNPJ breast cancer2021

OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer.

Jonas Steenbrugge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.